Creyos announced real-world outcomes from its deployment across more than 35 sites at Claremedica, a value-based primary care organization serving over 34,000 Medicare Advantage patients. Over a seven-month period, replacing the paper-based MMSE with Creyos' digital cognitive assessment enabled Claremedica to identify over 90% of new dementia cases at the early or mild stages while reducing average screening times from roughly 12 minutes to six minutes.
Our readValue-based care buyers evaluate digital screeners on both operational efficiency and diagnostic sensitivity. This named health system outcome validates that the platform can halve administrative screening time without sacrificing clinical rigor, enabling earlier intervention and proactive care planning for Medicare Advantage populations.